IgA Nephropathy

Vor Bio (VOR) announced positive Phase 3 results for telitacicept in IgA nephropathy (IgAN) patients in China. The study met its primary endpoint, demonstrating a statistically significant 58.9% reduction in proteinuria versus 8.8% for placebo at Week 39 (p<.0001). Telitacicept also showed stabilization of kidney function and a reduced risk of eGFR decline. Serious adverse events were less frequent with telitacicept. RemeGen has submitted a BLA to China’s CDE for telitacicept in IgAN.

CSL Vifor and Travere Therapeutics acknowledge the updated KDIGO 2025 guidelines for IgA Nephropathy (IgAN). These guidelines refine diagnostic criteria, treatment goals, and therapeutic approaches for this leading cause of kidney failure. Notably, FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is highlighted as a potential first-line treatment option for managing IgAN-induced nephron loss, contrasting the traditional RASi-first approach. The guidelines cite the PROTECT trial, demonstrating FILSPARI’s efficacy compared to optimized RASi therapy. Experts believe the updated guidance will improve treatment decisions and long-term kidney outcomes.